Nonalcoholic steatohepatitis (NASH) is a massive public health challenge; Sino Biological is currently producing a huge range of NASH related drug targets and reagents.
On Friday, Sagimet Biosciences, a clinical-stage biopharmaceutical company, filed with the SEC to raise up to $75 million in an initial public offering for the second time. It had previously filed in April 2021 to raise $75 million before withdrawing in March 2022. The company is focused on developing novel therapeutics called fatty acid synthase (FASN) inhibitors targeting dysfunctional metabolic pathways in diseases. The lead drug candidate, denifanstat, is an oral, once-daily pill and selecti